NOVAVAX COVID-19 VACCINE APPROVED FOR CANADIANS 18+
Feb 17, 2022
By Bob Komsic
The COVID-19 vaccine from Novavax has finally received approval for use in Canadian adults.
Health Canada’s approval comes about a year and a half after the federal government announced a deal to produce the vaccine, known as Nuvaxovid, at the National Research Council site in Montreal.
It’s the first protein-based vaccine to be approved in the country as opposed to the newer mRNA technology used in the Pfizer and Moderna shots.
Experts feel this could win over some vaccine-hesitant Canadians who still have not received a dose of any vaccine.
The two-dose vaccine has demonstrated 90% effective at preventing symptomatic COVID-19 and 100% effective at preventing severe disease.
Health Canada is recommending the interval be at least 21-days based on clinical trials.
The National Advisory Committee on Immunization is advising Nuvaxovid can be used for a primary series or a third dose for those who’ve been ”unable, due to contraindications, or not willing to receive an mRNA COVID-19 vaccine.”